BLFS · CIK 0000834365 · operating
BioLife Solutions develops and manufactures bioproduction products and services for the cell and gene therapy (CGT) industry. The company's portfolio includes proprietary biopreservation media formulations such as HypoThermosol FRS and CryoStor Freeze Media, which are designed to preserve cellular integrity during cryopreservation. The company also produces bioproduction tools including human platelet lysates for cell expansion, CellSeal closed system vials, and the ThawSTAR line of automated thawing devices for frozen cell and gene therapies. Additionally, BioLife Solutions offers evo shipping containers—cloud-connected passive storage and transport systems for temperature-sensitive biologics and pharmaceuticals.
The company's products serve customers engaged in basic research, applied research, and commercial manufacturing of cell and gene therapy products. BioLife Solutions distributes its offerings through both direct sales and third-party distributors across North America, Europe, the Middle East, Africa, and other international markets.
Incorporated in Delaware in 1987, BioLife Solutions is headquartered in Bothell, Washington, and maintains a market capitalization of approximately $1.1 billion. The company is publicly listed on Nasdaq.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-0.10 | $-0.09 | +77.3% | |
| 2024 | $-0.44 | $-0.44 | +71.1% | |
| 2023 | $-1.52 | $-1.52 | +53.8% | |
| 2022 | $-3.29 | $-3.29 | -1545.0% | |
| 2021 | $-0.20 | $-0.20 | -566.7% | |
| 2020 | $-0.03 | $0.09 | -108.6% | |
| 2019 | $0.35 | $0.42 | +150.0% | |
| 2018 | $0.14 | $0.18 | — | |
| 2017 | — | — | — | |
| 2016 | — | — | — | |
| 2015 | — | — | — | |
| 2014 | — | — | — | |
| 2013 | — | — | — | |
| 2012 | — | — | — | |
| 2011 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-26 | 0001628280-26-012294 | SEC ↗ |
| 2024-12-31 | 2025-03-03 | 0001628280-25-009511 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001628280-24-008061 | SEC ↗ |
| 2022-12-31 | 2023-03-31 | 0001437749-23-008875 | SEC ↗ |
| 2021-12-31 | 2022-03-31 | 0001437749-22-007869 | SEC ↗ |
| 2020-12-31 | 2021-03-31 | 0001437749-21-007867 | SEC ↗ |
| 2019-12-31 | 2020-05-15 | 0001437749-20-011046 | SEC ↗ |